REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  05/25 04:00:01 pm EDT
690.88 USD   +0.71%
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
05/23Fda approves dupixent (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
AQ
05/23Evkeeza (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ultra-rare form of high cholesterol
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza

01/07/2022 | 07:34am EDT

By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc. on Friday said they signed an international licensing agreement for Regeneron's cholesterol drug Evkeeza.

Under the agreement, Ultragenyx, a Novato, Calif., biopharmaceutical company, will develop, commercialize and distribute Evkeeza in countries outside the U.S., including in the European Economic Area, where Evkeeza was approved in June 2021.

Regeneron will receive a $30 million upfront payment and is eligible to receive up to $63 million in potential regulatory and sales milestones, the companies said.

Tarrytown, N.Y., biotechnology company Regeneron discovered Evkeeza and launched the drug in the U.S. last February for patients with homozygous familial hypercholesterolemia, an ultra-rare inherited form of high cholesterol. Regeneron said it will continue to solely sell Evkeeza in the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

01-07-22 0734ET

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS, INC. 0.71% 690.88 Delayed Quote.9.40%
ULTRAGENYX PHARMACEUTICAL INC. 0.26% 45.92 Delayed Quote.-45.39%
All news about REGENERON PHARMACEUTICALS, INC.
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
05/23Fda approves dupixent (dupilumab) as first treatment for adults and children aged 12 an..
AQ
05/23Evkeeza (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ul..
AQ
05/23FDA approves Dupixent« (dupilumab) as first treatment for adults and children aged 12 ..
AQ
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform With $738 Price Target
MT
05/23Regeneron's Phase 3 Trial Data Shows Positive Results for Potential Treatment of Rare H..
MT
05/21Evkeeza« (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with U..
PR
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
05/20FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 835 M - -
Net income 2022 4 041 M - -
Net cash 2022 8 670 M - -
P/E ratio 2022 18,7x
Yield 2022 -
Capitalization 74 440 M 74 440 M -
EV / Sales 2022 5,56x
EV / Sales 2023 4,92x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 690,88 $
Average target price 691,67 $
Spread / Average Target 0,11%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.9.40%74 440
GILEAD SCIENCES, INC.-10.47%80 715
VERTEX PHARMACEUTICALS23.33%68 665
WUXI APPTEC CO., LTD.-22.98%40 017
BIONTECH SE-40.07%37 546
GENMAB A/S-19.24%20 071